Skip Mediastinal Lymph Node Metastasis and Lung Cancer: A Particular N2 Subgroup With a Better Prognosis

Size: px
Start display at page:

Download "Skip Mediastinal Lymph Node Metastasis and Lung Cancer: A Particular N2 Subgroup With a Better Prognosis"

Transcription

1 Skip Mediastinal Lymph Node Metastasis and Lung Cancer: A Particular N2 Subgroup With a Better Prognosis Marc Riquet, MD, Jalal Assouad, MD, Patrick Bagan, MD, Christophe Foucault, MD, Françoise Le Pimpec Barthes, MD, Antoine Dujon, MD, and Claire Danel, MD Departments of Thoracic Surgery and Pathology, Surgical Center, Boisguillaume and Georges Pompidou European Hospital, Paris, France Background. Lymph node (LN) metastases from lung cancer may skip the intrapulmonary nodes directly to the mediastinum ([N1 ]N2 vs [N1 ]N2). This phenomenon is frequent. Patients with such a metastatic pattern appear to have a better prognosis following surgery. Our purpose was to further study the clinical significance and prognostic value of this particular group of (N1 )N2 patients. Methods. We retrospectively analyzed the data of 731 patients with a pn2 stage who underwent resection for non-small cell lung cancer. Patients with (N1 )N2 metastases (n 209) were compared to patients with intrapulmonary (N1 )N2 (n 522). Results. In the (N1 )N2 group, lobectomies were more frequent (54% vs 33%, p 0.00), metastases more frequently involved a single LN station (79.4% vs 56.3%, p < ), and primary tumor was more often located in the upper lobes (67.4% vs 55.6%, p ). (N1 )N2 was a factor of better prognosis (5 year survival rates 34.4% vs 18.5%, p ), which proved also significant when only a single station was involved (38.4% vs 24%, p ). These results were confirmed by multivariate analysis. Conclusions. (N1 )N2 skip metastasis is a unique subgroup of pn2 disease. Lung lymph drainage anatomy may explain the occurrence of these metastases. They form an independent prognostic factor of survival suggesting the need for further study, the results of which may lead to better knowledge of lung cancer, improved classification, and adapted adjuvant therapy. (Ann Thorac Surg 2005;79:225 33) 2005 by The Society of Thoracic Surgeons The international staging system for non-small cell lung cancer (NSCLC) [1] defines regional lymph node (LN) involvement as N1: metastasis to LN in the peribronchial or the ipsilateral hilar region or both, including direct extension; and as N2: metastasis to ipsilateral mediastinal LN (MLN) and subcarinal LN. N2 disease significantly worsens the prognosis [1, 2]. In 1971, Kirsh and colleagues [3] noted the absence of N1 disease in patients with N2 metastases. In 1986, Libshitz and colleagues [4] focused a study on this entity. The entity they called skip phenomenon was present in 29.2% (14 of 48) of N2 patients, representing 7% (14 of 200) of all patients undergoing resection for NSCLC. This condition of skip LN metastasis consisting of N2 disease without N1 involvement appeared to be more frequent in case of adenocarcinomas (10 of 14 patients). Other studies have reported this N2 subgroup to be more frequent in case of upper lobe NSCLC (43 of 62 patients) [5] and to consist most often in the involvement of only one MLN station (30 of 33 patients) [6]. This last study [6] and more recent studies [7 12] suggest that skip MLN metastases (N1 ) tend to have a better prognosis in NSCLC than when Accepted for publication June 16, Address reprint requests to Dr Riquet, Service de Chirurgie Thoracique, Hôpital Européen Georges Pompidou, 20 Rue Leblanc Paris, France; marc.riquet@hop.egp.ap-hop-paris.fr. associated with N1 involvement. The purpose of this study was to further elucidate the clinical significance and prognostic value of skip MLN metastases by comparing 209 skip (N1 )N2 patients with 522 (N1 )N2 patients operated for NSCLC during the same period. Material and Methods Patients Between 1984 and 2001 a total of 2,863 patients underwent pulmonary surgical resection for NSCLC at Georges Pompidou European Hospital and at Boisguillaume surgical center. The surgical procedure was a potentially curative complete resection in combination with hilar and mediastinal lymphadenectomy. Patients with typical carcinoid tumor and patients who had preoperative neoadjuvant chemotherapy or radiation therapy or who had palliative surgery were excluded from the study. Pathological N classification was N0 54.1% (n 1,548), N1 20.4% (n 584), and N2 25.5% (n 731). The 731 pn2 patients form the basis of this study. Patient s ages ranged from 30 to 88 years (mean 61 years). The group included 598 males and 133 females. Skip MLN metastases (N1 )N2 were demonstrated in 209 patients (28.6%) and MLN metastases associated with N1 disease (N1 )N2 in 522 patients (71.4%). Postoperative adjuvant 2005 by The Society of Thoracic Surgeons /05/$30.00 Published by Elsevier Inc doi: /j.athoracsur

2 226 RIQUET ET AL Ann Thorac Surg SKIP MEDIASTINAL LN METASTASIS 2005;79: therapy was performed in 515 patients in a nonrandomized fashion according to specific management adopted by the different referring physicians: 405 patients received adjuvant radiation therapy and 110 patients received both radiation and chemotherapy or chemotherapy alone. The type of pn2 involvement was not taken into consideration in the indication for adjuvant therapy. Method (N1 )N2 patients were compared with (N1 )N2 patients in terms of the following: some characteristics (clinical N estimation, past history of cancer, type of resection performed, histology, and adjuvant therapy); the location and site of the primary tumor as well as the site and extent of MLN metastasis; survival (overall survival rates, survival rates according to the number and location of MLN stations involved, histology, and adjuvant therapy); and cause of death (systemic metastasis, local recurrence, and others). For MLN involvement the classification of Mountain and Dresler [2] was used. The N2 population was divided in single mediastinal LN (SMLN) station N2, which is N2 involving a single station either in superior mediastinal nodes (2R 4R or 3 or 4L) or aortic nodes (5 or 6) or inferior mediastinal nodes (7 or 8 or 9) and dual mediastinal LN (DMLN) station N2, which is the involvement of two or more of any combination of the above mentioned stations. The 2R and 4R LN stations were grouped together because they form the same anatomical LN chain [13]. Follow-up information was obtained either from hospital case records, or a questionnaire completed by the local chest physician or general practitioner, or from death certificates. Zero time was considered as the date of surgery and January 2003 was the closing date of the study. Univariate analysis was conducted between both populations. Actuarial survival curves were calculated by Kaplan-Meier method; statistical comparisons were made using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. Multivariate analysis included gender, age, side of the tumor, type of surgical resection performed, histology, T, tumor size, type of N2, and adjuvant therapy. All data analyses were conducted with the two-sided test: a p value less than 0.05 was considered as statistically significant. Standard error of the mean software was used for calculation [14]. Results Characteristics Characteristics of both (N1 )N2 and (N1 )N2 populations are reported in Table 1. No statistical difference was observed concerning age, gender, past oncologic history, clinic N status, or adjuvant treatment. Pneumonectomy was performed more frequently in the case of (N1 )N2 patients (67% vs 46%, p 0.001). Postoperative complications occurred in 21% (44 of 209) and deaths in 4.3% (9 of 209) of (N1 )N2 patients and in 22.6% (118 of 521) and 6.9% (36 of 521) of (N1 )N2 patients (p 0.19). Following pneumonectomy, death occurred in 8.3% of (N1 )N2 patients and 8.3% of (N1 )N2 patients. Following lobectomy, death occurred in 0.9% of (N1 )N2 patients and in 3.6% of (N1 )N2 patients (p 0.33). Death complicated 2.6% of lobectomies (7 of 272 patients) and 8.3% of pneumonectomies (37 of 446 patients) (p ). Histology was not different between the (N1 )N2 and (N1 )N2 patient groups. However, when only SMLN stations subgroups are considered, adenocarcinomas and large cell lung cancers were more frequent in (N1 )N2 patients and squamous cell carcinomas in (N1 )N2 patients. No difference was observed among the groups concerning T status. When studying T1 and T2 together ((N1 )N2 [n 162] and (N1 )N2 [n 412]) to test visceral pleural involvement (VPI or ), there was also no difference: (N1 )N2 VPI 25.9% (42 of 112 patients) and (N1 )N2 VPI 30.6% (126 of 412 patients). (N1 )N2 was more frequent when tumor size exceeded 5 cm in diameter (p 0.03). Site and Extent of MLN Metastases Tumor location and MLN involvement are reported in Table 2. (N1 )N2 was observed more frequently on the right (57.9% vs 50.9%, p 0.08). (N1 )N2 was more frequent in patients with primary tumors in the upper lobes (p ). Among the (N1 )N2 patients, 79.4% exhibited metastases in a SMLN station and 20.8% in DMLN stations: the frequency of a SMLN station involvement was significantly less among (N1 )N2 patients (56%; p ). The SMLN station involvement, according to the location of the primary tumor, is reported in Table 3: 8 out of 62 (12.9%) right upper lobe tumors metastasized into the inferior mediastinum LN station 7, and 3 out of 41 (7.3%) left upper lobe tumors metastasized into the inferior mediastinum LN station 7 and 9. Inversely, 4 out of 31 (12.9%) right lower lobe tumors metastasized into the superior mediastinum LN station 4R, and 9 out of 15 (60%) left lower lobe tumors metastasized into superior mediastinum LN station, 5 and 4L. Inferior mediastinal LN station 7 involvement was present in 28.3% (47 of 166) of (N1 )N2 patients and in 39.8% (117 of 294) of (N1 )N2 patients when only a SMLN station was involved, and respectively, in 58.1% (25 of 43 patients) and 74.6% (170 of 228 patients) when dual station was involved. Survival Survival of the entire population including both (N1 )N2 and (N1 )N2 disease is reported in Table 4. Gender, histology, side of the primary tumor, and previous oncologic history were not factors of poor prognosis. Factors of significant improved prognosis were lobectomy versus pneumonectomy, SMLN station involvement, clinical N0 disease, and adjuvant therapy with chemotherapy. p(n1 )N2 disease was a factor of better prognosis as

3 Ann Thorac Surg RIQUET ET AL 2005;79: SKIP MEDIASTINAL LN METASTASIS 227 Table 1. Main Characteristics of (N1 )N2 and (N1 )N2 Populations Characteristics (N1 )N2 (Skip ) n 209 (N1 )N2 (Skip ) n 522 p Value Age mean Not significant range Sex male/female 175/34 423/ Histology Squamous 78 (37.3%) 231 (44.2%) Adenocarcinoma 84 (40.2%) 204 (39.1%) Large cell 26 (12.4%) 39 (7.5%) 0.16 Other 8 (3.8%) 23 (4.4%) Neuroendocrine 13 (6.2%) 25 (4.8%) Histology single station Squamous 61 (36.7%) 149 (50.7%) Adenocarcinoma 69 (41.6%) 98 (33.3%) Large cell 22 (13.3%) 22 (7.5%) Other 14 (8.4%) 25 (8.5%) Histology dual stations Squamous 17 (39.5%) 82 (36.0%) Adenocarcinoma 15 (34.9%) 106 (46.5%) 0.19 Large cell 4 (9.3%) 7 (3.0%) Other 7 (16.3%) 33 (14.5%) Past oncological history (yes/no) 30/179 (34.9%) 56/466 (27.8%) 0.17 Clinical N2 (a) 136/69 (66.3%) 373/142 (72.4%) 0.11 Pneumonectomy 96 (45.9%) 350 (67.0%) Lobectomy-segmentectomy 113 (54.1%) 172 (33.0%) T factor T1 50 (23.9%) 90 (17.2%) T2 112 (53.6%) 322 (61.9%) T3 41 (19.6%) 89 (17.0%) 0.1 T4 6 (2.9%) 21 (4.0%) Size 3 cm 51 (24.4%) 173 (26.2%) 3cm S 5 cm 70 (35.5%) 216 (41.4%) cm 88 (42.1%) 169 (32.4%) Adjuvant treatment No T 69 (33.2%) 142 (27.4%) CT 12 (15.9%) 26 (14.9%) 0.22 RCT RT 106 (50.9%) 299 (57.7%) a Data not available: n 11. CT chemotherapy; not no adjuvant treatment; RT radiation therapy; RCT radiation and chemotherapy; S size. compared to (N1 )N2 disease (5 year survival rates 34.4% vs 18.5%, p ) (Fig 1). This was also the case when only a SMLN station was involved (38.4% vs 24%, p ) (Fig 2), whereas prognosis was similar in case of DMLN station involvement (Fig 3). (N1 )N2 DMLN station involvement and (N1 )N2 SMLN station involvement proved to have similar prognostic value (24.1% vs 20.7%, p 0.29). Differences in survival between (N1 )N2 and (N1 )N2 involvement with respect to gender, histology, location, and site of the tumor, clinical N2 or surgical N2, adjuvant therapy, and past oncologic history had no prognostic significance. Differences were significant only when considering T status (T1 vs T3 T4) and type of resection (lobectomy vs pneumonectomy), and remained significant when only (N1 )N2 SMLN station involvement was considered (respectively, p 0.02 and 0.018). In case of (N1 )N2 SMLN station involvement, the stations involved (4R, 5, 4L, 9) had the similar prognostic value: 4R (n 58) 5 year survival, 38.6%; 9 (n 45), 35.5%; 5 (n 32), 36.3%; 4L (n 16), 55%.

4 228 RIQUET ET AL Ann Thorac Surg SKIP MEDIASTINAL LN METASTASIS 2005;79: Table 2. Tumor Location and Mediastinal Lymph Node Involvement TL (N1 )N2 (skip ) n 209 (N1 )N2 (skip ) n 522 p Value Right/left 121/88 (57.9%/42.1%) 265/257 (50.8%/49.2%) Lobe Upper lobe 133 (69.3%) 266 (57.1%) Lower lobe 59 (30.7%) 200 (42.9%) Right upper lobe 69 (57.0%) 124 (46.8%) Middle lobe 9 (7.4%) 13 (4.9%) Right lower lobe 37 (30.5%) 101 (38.1%) Right main bronchus 6 (4.9%) 27 (10.1%) Left upper lobe 64 (72.2%) 142 (55.3%) Left lower lobe 22 (25.0%) 99 (38.5%) Left main bronchus 2 (2.3%) 16 (6.3%) Station involved (Single/dual) 166/43 (79.4%) 294/228 (56.3%) TL tumor location within the lung. Cause of Death Death occurred in 78.4% (544 of 694) patients during follow-up. Deaths due to NSCLC were more frequent in case of (N1 )N2 disease, which tends to confirm the better prognosis observed in case of (N1 )N2 metastases (but this was not significant): (N1 )N2: SMLN station 62.3% (134 of 215 patients), DMLN station 70.6% (130 of 184 patients); (N1 )N2: SMLN station 54.8% (57 of 104 patients), DMLN station 60% (21 of 35 patients). Multivariate Analysis Multivariate analysis, using the Cox proportional hazard model, demonstrated a poor prognosis for the following: age (p ), tumor size (p ), pneumonectomy (p 0.045\odds ratio [OR] 1.23\confidence interval [CI][1.00 to 1.49]), no adjuvant therapy (p 0.004\OR 1.30\CI[1.00 to 1.67]), adenocarcinoma (p \OR 1.27\CI[1.07 to 1.51]), DMLN station (p \OR 1.52\CI[1.27 to 1.82]), (N1 )N2 (p \OR 1.33\CI[1.09 to 1.62]). Multivariate analysis of SNLM station involvement confirmed (N1 )N2 to be the only factor of poor prognosis (p \OR 1.41\CI[1.11 to 1.78]), besides age and tumor size. Comment Main (N1 )N2 characteristics collected from the literature are reported in Table 5. pn2 disease is encountered in 17.6% to 26.5% of patients operated on for NSCLC with complete MLN dissection [4, 6, 8, 9, 12, 15]. Six studies [4, 6, 8, 9, 12, 15] reported 715 pn2 out of 3,415 patients (20.9%). The frequency of (N1 )N2 disease ranges from 20.2% to 38% with a mean of 32.7% (234 of 715) patients [4, 6, 8, 9, 12, 15]. Our results are within the ranges of these percentages. However, pn2 25.5% is among the highest percentage, whereas p(n1 )N2 28.6% is among the lowest. Whatever the series considered, p(n1 )N2 appears to be an important subgroup of N2 patients. The presence of intrapulmonary node disease is influenced by the rigor in which the nodes are searched for by the pathologist. Our study started twenty years ago with the aim of Table 3. Single LN Stations Involved According to Primary Tumor Location (Right 261; Left 197) Numbered According to the New International Classification [2] Right Mediastinal Lymph Node Station Left Mediastinal Lymph Node Station Lobe Involved 4R 3p 9 6(3a) L (N1 )N2 Upper lobe n 166 Middle Lobe 3 3 R 102 Lower lobe L 64 Main bronchus Total 58 (34.9%) 41 (27.7%) 6 (3.6%) 34 (20.5%) 17 (10.2%) (N1 )N2 Upper lobe n 294 Middle Lobe 5 4 R 159 Lower lobe L 133 Main bronchus Total 82 (27.9%) 74 (25.2%) 43 (14.6%) 43 (14.6%) 38 (12.9%) R right; L left.

5 Ann Thorac Surg RIQUET ET AL 2005;79: SKIP MEDIASTINAL LN METASTASIS 229 Table 4. N2 Patient Survival (n 694) Factors n Median 5 Year Survival p Value Gender Male NS Female Histology Adenocarcinoma Squamous NS Large cell Other Neuroendocrine T T T T T Pneumonectomy Lobectomysegmentectomy Clinical N2 a 0.02 mn cn Left Right Past oncologic history Yes No N2 single station N2 dual stations N1 N N1 N N1 N2 1 station N1 N2 1 station Adjuvant treatment b no CT CT or RCT a unavailable data n 11; b unavailable data n 5. Postoperative deaths are excluded (n 45). cn2 clinical N2; CT chemotherapy; mn2 microscopic N2; no CT no chemotherapy (are included: no adjuvant treatment and radiation therapy alone); NS not significant; RCT radiation and chemotherapy. Fig 1. Five year survival rates: comparison between (N1 )N2 (n 204) and (N1 )N2 (n 490) patients (all mediastinal lymph node station involved); postoperative death excluded. (1 (N1 )N2 [5 year survival rate: 34.4%, median 28 months]; 2 (N1 )N2 [5 year survival rate: 8.5%, median 18 months]). This was not different when postoperative death was included: (N1 )N2 (33%, median 27); (N1 )N2 (17%, median 17) (p ). commonly involving only one positive MLN are another example of the importance of MLN dissection [12]. Some authors [4, 15] suggest that adenocarcinomas are more likely to have (N1 )N2 metastases than squamous cell carcinomas. Most studies, including our own, show no difference in the incidence of (N1 )N2 metastasis according to histology of the primary tumor when both SMLN and DMLN involved stations are considered together. When considering (N1 )N2 metastasis in a SMLN station, we observed that adenocarcinoma was, however, significantly more frequent. As others, we have found no explanation for this possible predominance of studying NSCLC lymphatic spread and the pathologists searched the nodes with rigor and accuracy. The frequency of N2 disease encountered in the literature depends on how hard this is searched for preoperatively. When N2 is discovered before surgery, many centers use preoperative neoadjuvant therapy, thus rendering (N1 )N2 disease difficult to assess. This is the reason why we excluded such patients from the study. Furthermore, during most of the considered period, even patients with bulky N2 were considered for surgery when resectable. Finally, skip metastases are more systematically detected by MLN dissection than by sampling [12]. Apart from micrometastasis detection, skip metastases Fig 2. Five year survival rates: comparison between (N1 )N2 (n 161) and (N1 )N2 (n 278) patients (single mediastinal lymph node station involvement only); postoperative deaths excluded. (1 (N1 )N2 [5 year survival rate: 38.4%, median 32 months]; 2 (N1 )N2 [5 year survival rate: 24.1%, median 23 months]). This was not different when postoperative death was included: (N1 )N2 (37.2%, median 30), (N1 )N2 (22.7%, median 21) (p ).

6 230 RIQUET ET AL Ann Thorac Surg SKIP MEDIASTINAL LN METASTASIS 2005;79: Fig 3. Five year survival rates: comparison between (N1 )N2 (n 43) and (N1 )N2 (n 212) (dual mediastinal lymph node station involvement); postoperative death excluded. (1 (N1 )N2 [5 year survival rate: 20.7%, median 17 months]; 2 (N1 )N2 [5 year survival rate: 11.2%, median 14 months]). This was not different when postoperative death was included: (N1 )N2 (20.7%, median 17), (N1 )N2 (10.4%, median 13) (p 0.096). adenocarcinoma in case of (N1 )N2. We wonder whether this would not be purely coincidental. In fact, SMLN station (N1 )N2 appears of good prognosis in our series and others, whereas adenocarcinomas commonly appear of poor prognosis: both results are contradictory. The biological behavior of tumor cells participating in (N1 )N2 involvement could be another explanation [6], but this remains purely hypothetical. Yoshino and colleagues [6] state that there is no difference in the location of the cancer within the lung and the presence of (N1 )N2 or (N1 )N2 involvement. Most other authors observed a higher incidence of (N1 )N2 metastases in upper lobe primaries but not significant [4, 5, 9]. Our study (Table 2) demonstrates it to be highly significant. In a previous anatomic study [13] on 260 cadavers we reported a 23.6% incidence of segmental lymph channels draining directly into mediastinal nodes. These direct draining lymph channels were more frequent from the upper lobes (36.4% on the right and 33.6% on the left). Both our anatomic and surgical results suggest that the possible mechanisms of (N1 )N2 metastasis is the anatomic lung lymph drainage pattern. The term skip metastasis refers to the concept that a LN located along lymphatic drainage channels between primary tumor and central nodal metastasis is not itself the site of metastasis. It is preferable to use the term (N1 )N2 when anatomy has demonstrated direct lymphatic drainage from the lung to MLN bypassing N1 nodes. Other explanations provided for the presence of skip metastasis are a particular biological behavior of tumor cells [6] or the presence of possible N1 micrometastasis overlooked by routine histopathological methods, which can occur despite the rigor of the pathologist [9]. We suggest another explanation: tumors with visceral pleural involvement (VPI) present a higher frequency of single or dual station N2 involvement [16]. This may be due to desquamating tumor cells within the pleural space, which are reabsorbed by lymphatic vessels of the parietal or diaphragmatic pleura; such drainage involves MLN stations [17] and theoretically induces (N1 )N2 involvement. However, our study does not demonstrate this possible role of the VPI for (N1 )N2 metastasis (VPI : (N1 )N2 25.9%, (N1 )N2 30.6%). Yoshino and colleagues [6] and Sagawa and colleagues [10] mentioned a possible higher incidence of SMLN station involvement in (N1 )N2 as compared to (N1 )N2. In our study, this is confirmed to be highly significant. Such a difference can also be explained by anatomic consideration. In our anatomic study [13], MLN are reached by two separate lymph channels in 14% of dissections. In case of (N1 )N2 dual stations, both lymph drainage may be (N1 )N2 but in some cases there may be one (N1 )N2 coexisting with one (N1 )N2 involvement (Fig 4): in such a case pn classification will be (N1 )N2 and dual (N1 )N2 involvement thus appears more frequent. (N1 )N2 involvement can concern each MLN station, whatever the cancer location within the lung. However, Okada and colleagues [15] believe that dissection of the subcarinal nodes in patients with an upper lobe tumor is not routinely necessary, especially when the nodes in both the hilum and upper mediastinum are intact, because of the rarity of (N1 )N2 subcarinal disease from upper lobes. In our study, we observed metastasis from the upper lobes into the MLN station 7 in 11 out of 103 patients (10.7%); such a pattern is also demonstrated by anatomic results in 10.4% of cases on the right [13]. Watanabe and colleagues [18] also report that the frequency of skipping metastases from the upper lobe tumors to the lower part of the mediastinum was 8.7%. We suggest that such percentages are sufficient for also supporting complete MLN dissection when operating NSCLC. The type of resection is not mentioned by authors studying skip (N1 )N2 metastases, with the exception of Gunluoglu and colleagues [8] who reported a percentage of 52.9% pneumonectomy and Misthos and colleagues [12] who reported 38%. These authors [8, 12] report that lobectomy appears to be more frequently performed than pneumonectomy in cases of (N1 )N2. This is demonstrated by our study and is easily explained by the absence of interlobar N1, rendering lobectomy easier to perform. Our percentage of pneumonectomy (61%) for N2 patients is higher than those reported in North America and Japan. However, it is similar to those of other European countries (62.5% [19], 64.6% [20], and 66% [21]. This is due to the fact that most patients were not selected and directly underwent surgery. Thus, the percentage of clinical N2 patients in our study was 70.7% (Table 1). In the study of Misthos and colleagues [12] the percentage of pneumonectomy was 38% but clinical N2 disease was not included and patients were entered in an induction chemotherapy protocol. The postoperative mortality rate we observed is due to this high number of pneumonectomies, which remains within the range of what is commonly reported (4.8% 18%) [22]. The difference in long-term survival has generally been slightly

7 Ann Thorac Surg RIQUET ET AL 2005;79: SKIP MEDIASTINAL LN METASTASIS 231 Table 5. Main (N1 )N2 Characteristics Collected From the Literature Characteristics Libshitz & Al 1986 [4] Tateihi & Al 1994 [5] Yoshino & Al 1996 [6] Gunluoglu & Al 2002 [8] Prenzel & Al 2003 [9] Misthos & Al 2004 [12] N2/N0 N1 (%) 48/200 (24%) 186/872 (21%) 110/619 (17.8%) 34/128 (26.5%) 45/256 (17.6%) 151/580 (26%) (N1 )N2/(N1 )N2 (%) 14/48 (29.2%) 62/186 (33%) 33/110 (30%) 11/34 (32.3%) 17/45 (38%) 44/151 (29%) Histology Adenocarcinoma 11 (78.6%) 30 (48.4%) 16 (48.5%) 6 (53%) 13 (29.6%) Squamous 0 24 (38.7%) 16 (48.5%) 9 (35%) 31 (70.4%) Large cell 2 (14.3%) 7 (11.3%) 1 (3%) 2 (12%) 0 Other 1 (7.1%) 1 (1.6%) T factor T1 9 (14.5%) 9 (27.3%) 4 (23.5%) 0 T2 35 (67.3%) 20 (60.6%) 11 (64.7%) 25 (57%) T3 9 (14.5%) 4 (12.1%) 2 (11.8%) 19 (43%) T4 9 (14.5%) RUL LUL RLL ML LLL Pneumonectomy 5 (45.5%) 19 (42.8%) Lobectomy 6 (54.5%) 25 (57.2%) Station 2R 4R Station 7 6 Station 9 (R) Station 9 (L) 7 Station 5/ Station 4 L 1 RUL and LUL 1 and 2 7 and 4 1 and 3 2 and 1 Station 7 (and 9) 3 (and 0) 8 (and 3)?? RLL and LLL 9 and 4 5 and 2 0 and 3 Station 4 and 5 0 and 0 Clinical N2 9 (27.3%) LLL left lower lobe; LUL left upper lobe; ML middle lobe; RLL right lower lobe; RUL right upper lobe. worse for patients requiring pneumonectomy [23], which is significant in our study. The need for less pneumonectomy probably participates in the more favorable outcome observed following surgery for (N1 )N2 metastases. Fig 4. Example of dual mediastinal lymph node station involvement with coexisting (N1 )N2 and (N1 )N2 involvement. pn classification is (N1 )N2. Coexisting (N1 )N2 is underrated and (N1 )N2 involvement thus appears more frequent. In fact, (N1 )N2 is of significantly better prognosis than (N1 )N2 metastasis. Data collected from the literature are reported in Table 6: global 5 year survival rates are higher in case of (N1 )N2 [6, 7, 9 11]. N2 disease as a whole is also characterized by higher 5 year survival rates when SMLN station is involved compared to DMLN station involvement [6, 7, 10, 11]. We also found the better prognostic value of single station N2 involvement to be highly significant (Table 4). It has been suggested that the improved (N1 )N2 prognosis be explained by the lesser frequency of DMLN station involvement [6]. This is also supported by observing that 5 year survival rates appear not significantly higher when (N1 )N2 SMLN station involvement was compared with (N1 )N2 SMLN station involvement (p 0.09 [6] and 0.08 [10]). In a previous study [24] including lesser patients ((N1 )N2 153, (N1 )N2 408) we also observed the difference in survival between (N1 )N2 and (N1 )N2 SMLN station as not significant: we believed that (N1 )N2 global poor prognosis was explained by the higher frequency of DMLN station involvement in that group [24]. Our current study significantly demon-

8 232 RIQUET ET AL Ann Thorac Surg SKIP MEDIASTINAL LN METASTASIS 2005;79: Table 6. Five Year Survival Rates (%) Collected From the Literature (N1 )N2 Tateishi and colleagues [5] n 62 22% Yoshino and colleagues [6] n 33 35% (N1 )N2 n 77 13% Total N2 n % (N1 )N2 SMLN Station n 26 31% n 30 38% NS p Yano and colleagues [7] n % Sagawa and colleagues [10] n 76 37% n % n % n % (N1 )N2 SMLN Station n 49 15% n 51 33% Gawryckowski and colleagues [11] n % p 0.02 p 0.08 n 41 0% p Prenzel and colleagues [9] n 17 41% n 28 14% n 15 48% n 24 13% p p strates that the prognosis of(n1 )N2 is better even in case of SMLN station involvement, which Prenzel and colleagues [9] also recently stressed on a smaller number of patients (n 45, with only 6 DMLN stations). We have no explanation for this better prognosis. Prenzel and colleagues [9] found a smaller number of tumor infiltrating MLN per patient in case of (N1 )N2 disease and suggest that this could explain the difference. The fact that (N1 )N2 SMLN station involvement shares the same poor prognosis as (N1 )N2 DMLN station involvement in our study supports this point of view. In a previous study, we demonstrated that survival rates were similar between extralobar N1 involvement and N2 involvement when N2 involvement was limited to a SMLN station [25]. With respect to anatomy, patients who have N2 disease and N1 nodes may have lymphatic channels that bypass N1 nodes and such patients have a better prognosis than patients who first seeded N1 nodes and then seeded N2 nodes. Since only the first nodes filtering the lymph channels from the primary tumor are seeded, SMLN station (N1 )N2 involvement may represent a particular N1 subgroup of patients. In conclusion, (N1 )N2 involvement is a frequent pstaging discovery. (N1 l)n2 demonstrates a better prognosis than other N2 subgroups. Further studies are needed to better understand this particular (N1 )N2 involvement. These results should lead to a better understanding of lung cancer, improved classification, and more appropriate adjuvant therapy. References 1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111: Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111: Kirsh MM, Kahn DR, Cago O, et al. Treatment of bronchogenic carcinoma with mediastinal metastases. Ann Thorac Surg 1971;12: Libshitz HI, McKenna RJ, Mountain CF. Patterns of mediastinal metastases in bronchogenic carcinoma. Chest 1986;90: Tateishi M, Fukuyama Y, Hamatake M, Kohdono S, Ishida T, Sugimachi K. Skip mediastinal lymph node metastasis in non-small cell lung cancer. J Surg Oncol 1994;57: Yoshino I, Yokoyama H, Yano T, et al. Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer. Ann Thorac Surg 1996;62: Yano T, Fukuyama Y, Yokoyama H, et al. Long-term survivors with pn2 non-small cell lung cancer after complete resection with a systematic mediastinal node dissection. Eur J Cardiothorac Surg 1998;14: Gunluoglu Z, Solah O, Metin M, Gurses A. The prognostic significance of skip mediastinal lymphatic metastasis in resected non-small cell lung cancer. Eur J Cardiothorac Surg (letter) 2002;21: Prenzel KL, Monig SP, Sinning JM, et al. Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer. J Surg Oncol 2003;82: Sagawa M, Sakurada A, Fujimura S, et al. Five year survivors with resected pn2 non-small cell lung carcinoma. Cancer 1999;85: Gawrychowski J, Gabriel A, Lackowska B. Heterogeneity of stage IIIA non-small cell lung cancer (NSCLC) and evaluation of late results of surgical treatment. Eur J Surg Oncol 2003;29: Misthos P, Sepsas E, Athanassiadi K, Kakaris S, Skottis I. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg 2004;25: Riquet M, Hidden G, Debesse B. Direct lymphatic drainage of lung segments to mediastinal nodes. J Thorac Cardiovasc Surg 1989;97: Kwiatkowski F. SEM (Statistiques, Epidémiologie, Médecine): un outil de gestion informatique et statistique

9 Ann Thorac Surg RIQUET ET AL 2005;79: SKIP MEDIASTINAL LN METASTASIS 233 adapté á la recherche en cancérologie. Bull Cancer 2000;87: Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection. J Thorac Cardiovasc Surg 1998;116: Manac h D, Riquet M, Medioni J, Le Pimpec Barthes F, Dujon A, Danel C. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg 2001;71: Okiemy G, Foucault C, Avisse C, Hidden G, Riquet M. Lymphatic drainage of the diaphragmatic pleura to the peritracheobronchial nodes. Surg Radiol Anat 2003;25: Watanabe Y, Shimizu J, Tsubota M, Iwa T. Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma: mediastinal nodal metastases in lung cancer. Chest 1990;97: Van Klaveren RJ, Festen J, Otten HJ AM, Cox AL, de Graaf R, Lacquet LK. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg 1993;56: Conill C, Astudillo J, Verger E. Prognostic significance of metastases to mediastinal lymph node levels in resected non small cell lung carcinoma. Cancer 1993;15: Regnard JF, Magdeleinat P, Azoulay D, et al. Results of resection for bronchogenic carcinoma with mediastinal lymph node metastases in selected patients. Eur J Cardiothorac Surg 1991;5: Klemperer J, Ginsberg RJ. Morbidity and mortality after pneumonectomy. Chest Surg Clin N Am 1999;9: Daly BDT. Late results. Chest Surg Clin N Am 1999;9: Riquet M, Dujon A, Le Pimpec Barthes F, et al. Cancer bronchiques N2 sans métastase aux ganglions intrapulmonaires. Ann Chir Thorac Cardiovasc 2003;7: 95(abstract). 25. Riquet M, Manac h D, Le Pimpec Barthes F, Dujon A, Chehab A. Prognostic significance of surgical pathologic N1 diseases in non-small cell carcinoma of the lung. Ann Thorac Surg 1999;67: The Thoracic Surgery Foundation for Research and Education The Thoracic Surgery Foundation for Research and Education (TSFRE) extends best wishes to all its colleagues and friends for We wish to extend our thanks not only for your support in the past year, but for the past many years. Your support of TSFRE has made a significant difference in the growth and accomplishments of the organization. Your past commitments to TSFRE have furthered many invaluable research and education activities that have made powerful differences in the practice of thoracic surgery. The transition period between the old year and the new year is also a time of reflection for many of us. We urge you to take this period of time to give some thought to the legacy you will be leaving behind, particularly within thoracic surgery. TSFRE would ask that you consider, in acknowledgment of what cardiothoracic surgery has done for you, the ways in which you might leave your legacy on our specialty. The great progress that cardiothoracic surgery has witnessed in the past decade is the result of extraordinary research and education activities. You can ensure that these vital programs continue well into the future, continuing to transform cardiothoracic surgery to help our patients. To do so, please consider the making of a planned gift to TSFRE. The most common planned gift is a charitable bequest to TSFRE through your will after you have properly ensured that your family and other loved ones will be financially secure. Under certain circumstances, a donation from your estate might give TSFRE $10,000 while representing only about $2,500 that would go to your family should the payment of estate, income and capital gains taxes be required. Real Estate as a planned gift can be a very practical mechanism, even if the real estate property has decreased in value. A donor may even give real estate and yet retain the use of the property. Sometimes a real estate gift can provide an ongoing source of income to the donor or to another designated individual. Through your generosity, you continue to allow our specialty to evolve. We urge you to continue to do so to your utmost capability by The Society of Thoracic Surgeons Ann Thorac Surg 2005;79: /05/$30.00 Published by Elsevier Inc

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

Prognostic Value of Histology in Resected Lung Cancer With Emphasis on the Relevance of the Adenocarcinoma Subtyping

Prognostic Value of Histology in Resected Lung Cancer With Emphasis on the Relevance of the Adenocarcinoma Subtyping GENERAL THORIC Prognostic Value of Histology in Resected Lung Cancer With Emphasis on the Relevance of the Adenocarcinoma Subtyping Marc Riquet, MD, PhD, Christophe Foucault, MD, Pascal Berna, MD, Jalal

More information

The Significance of One-Station N2 Disease in the Prognosis of Patients With Nonsmall-Cell Lung Cancer

The Significance of One-Station N2 Disease in the Prognosis of Patients With Nonsmall-Cell Lung Cancer ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,

More information

Visceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor

Visceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor Visceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor Dominique Manac h, MD, Marc Riquet, MD, PhD, Jacques Medioni, MD, Françoise Le Pimpec-Barthes, MD, Antoine Dujon,

More information

The accurate assessment of lymph node involvement is

The accurate assessment of lymph node involvement is ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo

More information

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

The metastatic behavior of renal cell carcinoma (RCC) Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors

The metastatic behavior of renal cell carcinoma (RCC) Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors Jalal Assouad, MD, Boriana Petkova, MD, Pascal Berna, MD, Antoine Dujon, MD, Christophe Foucault, MD, and Marc Riquet,

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

Non small cell lung cancer (NSCLC) with ipsilateral mediastinal

Non small cell lung cancer (NSCLC) with ipsilateral mediastinal Results of surgical intervention for p-stage IIIA (N2) non small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper

More information

Is the lymphatic drainage of lung cancer lobe-specific? A surgical appraisal

Is the lymphatic drainage of lung cancer lobe-specific? A surgical appraisal European Journal of Cardio-Thoracic Surgery 47 (2015) 543 549 doi:10.1093/ejcts/ezu226 Advance Access publication 29 May 2014 ORIGINAL ARTICLE Cite this article as: Riquet M, Rivera C, Pricopi C, Arame

More information

Lung cancer is a prevalent health problem worldwide. It is the leading cause

Lung cancer is a prevalent health problem worldwide. It is the leading cause Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II

LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer

Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer Yukinori Sakao, MD, PhD, Hideaki Miyamoto, MD, PhD, Akio Yamazaki, MD, PhD, Tsumin Oh, MD, Ryuta

More information

Visceral pleura invasion (VPI) was adopted as a specific

Visceral pleura invasion (VPI) was adopted as a specific ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,

More information

According to the current International Union

According to the current International Union Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

In the mid 1970s, visceral pleural invasion (VPI) was included

In the mid 1970s, visceral pleural invasion (VPI) was included ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information

Surgical resection is the first treatment of choice for

Surgical resection is the first treatment of choice for Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,

More information

Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer

Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Original Article Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Hiroaki Kuroda 1,2, Yukinori Sakao 1,2, Mingyon Mun 2, Noriko Motoi 3, Yuichi Ishikawa 3, Ken

More information

Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial

Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,

More information

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department

More information

Predictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study

Predictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study Moulla et al. Journal of Cardiothoracic Surgery (2019) 14:11 https://doi.org/10.1186/s13019-019-0831-0 RESEARCH ARTICLE Open Access Predictive risk factors for lymph node metastasis in patients with resected

More information

Selective lymph node dissection in early-stage non-small cell lung cancer

Selective lymph node dissection in early-stage non-small cell lung cancer Review Article Selective lymph node dissection in early-stage non-small cell lung cancer Han Han 1,2, Haiquan Chen 1,2 1 Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai

More information

Controversy continues to surround the role of surgery for patients

Controversy continues to surround the role of surgery for patients General Thoracic Surgery Keller et al Prolonged survival in patients with resected non small cell lung cancer and single-level N2 disease Steven M. Keller, MD, a Mark G. Vangel, PhD, b Henry Wagner, MD,

More information

Lung cancer involving neighboring structures is classified

Lung cancer involving neighboring structures is classified GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,

More information

Node-Negative Non-small Cell Lung Cancer

Node-Negative Non-small Cell Lung Cancer ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and

More information

Uniportal video-assisted thoracoscopic surgery segmentectomy

Uniportal video-assisted thoracoscopic surgery segmentectomy Case Report on Thoracic Surgery Page 1 of 5 Uniportal video-assisted thoracoscopic surgery segmentectomy John K. C. Tam 1,2 1 Division of Thoracic Surgery, National University Heart Centre, Singapore;

More information

Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer

Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,

More information

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery

More information

Staging of lung cancer based on the TNMclassification

Staging of lung cancer based on the TNMclassification The Prognostic Impact of Main Bronchial Lymph Node Involvement in Non-Small Cell Lung Carcinoma: Suggestions for a Modification of the Staging System Yoshihisa Shimada, MD, Masahiro Tsuboi, MD, PhD, Hisashi

More information

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018 30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective

More information

Prognostic Factors in Resectable Pathological N2 Disease of Non-small Cell Lung Cancer

Prognostic Factors in Resectable Pathological N2 Disease of Non-small Cell Lung Cancer Original Article 329 Prognostic Factors in Resectable Pathological N2 Disease of Non-small Cell Lung Cancer Chen-Ping Hsieh 1, Jui-Ying Fu 2, Yun-Hen Liu 1, Cheng-Ta Yang 2, Ming-Ju Hsieh 1, Ying-Huang

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;

More information

Carcinoma of the Lung in Women

Carcinoma of the Lung in Women Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma 244 Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma DAISUKE HOKKA 1, KAZUYA UCHINO 2, KENTA TANE 2, HIROYUKI OGAWA

More information

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No

More information

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro

More information

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki

More information

Xing Wang *, Shi Yan *, Yaqi Wang, Xiang Li, Chao Lyu, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu. Original Article.

Xing Wang *, Shi Yan *, Yaqi Wang, Xiang Li, Chao Lyu, Yuzhao Wang, Jia Wang, Shaolei Li, Lijian Zhang, Yue Yang, Nan Wu. Original Article. Original Article Adjuvant chemotherapy may improve outcome of patients with non-small-cell lung cancer with metastasis of intrapulmonary lymph nodes after systematic dissection of N1 nodes Xing Wang *,

More information

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new

More information

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail

More information

Skip Metastasis to the Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer

Skip Metastasis to the Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer Skip Metastasis to the Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer Ichiro Yoshino, MD, Hideki Yokoyama, MD, Tokujiro Yano, MD, Takashi Ueda, MD, Eiji Takai, MD, Kazuki Mizutani, MD, Hiroshi Asoh,

More information

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a

More information

T he increasing incidence and poor survival of patients

T he increasing incidence and poor survival of patients 710 LUNG CANCER Survival after resection for primary lung cancer: a population based study of 3211 resected patients T-E Strand, H Rostad, B Møller, J Norstein... See end of article for authors affiliations...

More information

The 8th Edition Lung Cancer Stage Classification

The 8th Edition Lung Cancer Stage Classification The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

Significance of Metastatic Disease

Significance of Metastatic Disease Significance of Metastatic Disease in Subaortic Lymph Nodes G. A. Patterson, M.D., D. Piazza, M.D., F. G. Pearson, M.D., T. R. J. Todd, M.D., R. J. Ginsberg, M.D., M. Goldberg, M.D., P. Waters, M.D., D.

More information

P sumed to have early lung disease with a favorable

P sumed to have early lung disease with a favorable Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,

More information

State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter?

State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter? Review Article State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter? Laura Romero Vielva 1, Manuel Wong Jaen 1, José A. Maestre Alcácer 2, Mecedes Canela Cardona

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer

Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer Original Article Surgical Treatment of Metachronous Nonsmall Cell Lung Cancer Shuji Haraguchi, MD, 1,2 Kiyoshi Koizumi, MD, 1,2 Tomomi Hirata, MD, 1,2 Kyoji Hirai, MD, 1,2 Iwao Mikami, MD, 1,2 Hirotoshi

More information

Difference of Sentinel Lymph Node Identification Between Tin Colloid and Phytate in Patients With Non Small Cell Lung Cancer

Difference of Sentinel Lymph Node Identification Between Tin Colloid and Phytate in Patients With Non Small Cell Lung Cancer of Sentinel Lymph Node Identification Between Tin Colloid and Phytate in Patients With Non Small Cell Lung Cancer Hiroaki Nomori, MD, PhD, Yasuomi Ohba, MD, Kentaro Yoshimoto, MD, Hidekatsu Shibata, MD,

More information

Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures

Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures Review Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures Hiroaki Nomori, MD, PhD, Kazunori Iwatani, MD, Hironori Kobayashi, MD, Atsushi Mori, MD, and

More information

History of Limited Resection for Non-small Cell Lung Cancer

History of Limited Resection for Non-small Cell Lung Cancer Review History of Limited Resection for n-small Cell Lung Cancer Haruhiko Nakamura, MD, PhD, 1 Sugishita Kazuyuki, MD, 1 rihito Kawasaki, MD, 1 Masahiko Taguchi, MD, PhD, 1 and Harubumi Kato, MD, PhD 2

More information

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,

More information

Visceral pleural invasion (VPI) of lung cancer has been

Visceral pleural invasion (VPI) of lung cancer has been ORIGINAL ARTICLE Visceral Pleural Invasion Classification in Non Small- Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a

More information

ACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)

ACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy) No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis

More information

Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer

Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,

More information

Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer

Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram

More information

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:

More information

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in

Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in 1 Manuscript type: Original Article DOI: Title: What has changed in the surgical treatment strategies of non-small cell lung cancer in twenty years? A single centre experience Short title: Changes in the

More information

11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?

11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor? MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009

More information

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung

More information

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive

More information

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,

More information

Hiroyasu Ueno, Aritoshi Hattori, Takeshi Matsunaga, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki

Hiroyasu Ueno, Aritoshi Hattori, Takeshi Matsunaga, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki Hiroyasu Ueno, Aritoshi Hattori, Takeshi Matsunaga, Kazuya Takamochi, Shiaki Oh, Kenji Suzuki Is Lower Zone Mediastinal Nodal Dissection Always Mandatory for Lung Cancer in the Lower Lobe? Department of

More information

Although metastasis in regional lymph nodes is one of

Although metastasis in regional lymph nodes is one of Nodal Occult Metastasis in Patients With Peripheral Lung Adenocarcinoma of 2.0 cm or Less in Diameter Jian Wu, MD, Yasuhiko Ohta, MD, Hiroshi Minato, MD, Yoshio Tsunezuka, MD, Makoto Oda, MD, Yoh Watanabe,

More information

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,

More information

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis

Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,

More information

Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer

Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Shin-ichi Takeda, MD, Shimao Fukai, MD, Hikotaro Komatsu, MD, Etsuo Nemoto, MD, Kenji

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Reasons for conversion during VATS lobectomy: what happens with increased experience

Reasons for conversion during VATS lobectomy: what happens with increased experience Review Article on Thoracic Surgery Page 1 of 5 Reasons for conversion during VATS lobectomy: what happens with increased experience Dario Amore, Davide Di Natale, Roberto Scaramuzzi, Carlo Curcio Division

More information

Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease)

Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease) Eur J Cardio-thorac Surg (1996) 10:649-655 Springer-Verlag 1996 P. De Leyn P. Schoonooghe G. Deneffe D. Van Raemdonck W. Coosemans J. Vansteenkiste T. Lerut Surgery for non-small cell lung cancer with

More information

Characteristics and Prognostic Value of Lymphatic and Blood Vascular Microinvasion in Lung Cancer

Characteristics and Prognostic Value of Lymphatic and Blood Vascular Microinvasion in Lung Cancer Characteristics and Prognostic Value of Lymphatic and Blood Vascular Microinvasion in Lung Cancer Alex Arame, MD, Pierre Mordant, MD, Aurélie Cazes, MD, Christophe Foucault, MD, Antoine Dujon, MD, Françoise

More information

Chirurgie beim oligo-metastatischen NSCLC

Chirurgie beim oligo-metastatischen NSCLC 24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital

More information

Controversies in management of squamous esophageal cancer

Controversies in management of squamous esophageal cancer 2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous

More information

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental

More information